Pre-Submission Review for Bioinformatics Papers

Bioinformatics reviewers usually ask:

• Can the code or software be accessed?
• Is the software maintained or installable?
• Are input and output formats defined?
• Are tool versions and parameters reported?
• Are sequencing, proteomics, or other omics data deposited?
• Are accession numbers and repository links available?
• Are benchmarks fair against current alternatives?
• Does the biological conclusion follow from the computational output?

If those surfaces are weak, better prose will not save the paper.

In our pre-submission review work, bioinformatics manuscripts often fail because the computational artifact is not as publication-ready as the manuscript. The paper describes a useful tool, but the repository is hard to install. The analysis is interesting, but versions and parameters are incomplete. The biological claim is exciting, but the data trail is too thin for reviewers to trust.

The common failure patterns are:

• Repository without reproducibility: code exists, but reviewers cannot run the core workflow.
• Data trail gap: raw or processed omics data are not deposited clearly enough.
• Benchmark asymmetry: the new method is compared against outdated, default, or weakly tuned alternatives.
• Implementation ambiguity: input, output, dependencies, and supported environments are unclear.
• Biology overreach: computational patterns are discussed as validated biology before validation exists.

A bioinformatics review should identify which one will dominate peer review.

Bioinformatics author guidance asks software papers to include an availability and implementation section. PLOS Computational Biology requires author-generated code related to findings to be publicly available at publication unless an exemption applies. Genome Biology requires an availability of data and materials statement, and Nature Portfolio journals require data availability statements for original research and treat code sharing as best practice when code is central to the conclusions.

Those policies point to one practical standard: bioinformatics manuscripts are judged as paper plus artifact.

Send the manuscript, target journal, code repository, installation instructions, software version, dependency file, test dataset, raw and processed data links, accession numbers, benchmark scripts, and the main biological claim.

If the repository is private before submission, include reviewer-access instructions. If data cannot be public for privacy reasons, explain access restrictions and the planned data availability statement.

A useful bioinformatics review should give authors a practical submission decision, not only comments on style.

The best review should say exactly what a reviewer would be unable to reproduce or trust. If the repository cannot recreate a main figure, that should be named directly. If the data statement is legally accurate but practically useless, that should be fixed before submission.

Use this bioinformatics page when the manuscript's central artifact is a tool, workflow, database, omics analysis, or software implementation. Use computational biology review when the paper's center of gravity is a model, simulation, theoretical framework, or broader computational study.

That difference matters for search intent and for the actual review. A bioinformatics author usually needs help with repositories, accessions, formats, pipeline documentation, and software usability. A computational biology author may need help with model assumptions, validation logic, reproducibility, or biological interpretation across a broader computational system.

Do not submit if:

• the README only makes sense to someone already in the lab
• the main workflow depends on undocumented local paths
• data access is promised but no accession or reviewer route exists
• the benchmark uses old tools because they were easier to beat
• biological language implies validation that the paper has not done

Those issues tend to become review blockers. They are cheaper to fix before submission than after a reviewer has lost trust in the artifact.

Before choosing a target, ask whether the paper is primarily a software note, methods paper, resource paper, biological discovery paper, or applied omics analysis. Bioinformatics, Genome Biology, PLOS Computational Biology, and field-specific biomedical journals reward different parts of the same work.

If the paper is a usable tool with limited biological novelty, a methods or software-focused journal may be cleaner. If the biological finding is the main contribution, the code still matters, but the journal will judge whether the biological insight is strong enough.

Use Manusights when the team needs a submission decision, not only technical cleanup. That means the paper is close to submission but the authors are unsure whether the artifact, benchmark, data package, and journal target are ready together.

If the repository simply needs engineering work, fix the repository first. If the manuscript needs a decision about whether reviewers will trust the full package, a readiness review is the better first move.